Minimal residual disease in hypopigmented mycosis fungoides.
We describe the case of a 13-year-old boy with stage I hypopigmented mycosis fungoides in whom minimal residual disease was detected with T-cell receptor gamma-polymerase chain reaction after the disease was in complete clinical remission. We further cloned and sequenced the T-cell receptor gamma-polymerase chain reaction product of the lesion in remission and found that the original T-cell clone still existed in decreased amounts. The patient was followed up for 3 1/2 years without any new lesions developing. The clinical significance of this residual malignant T-cell clone in mycosis fungoides remains to be elucidated.
Hsiao
Pa-Fan
PF
Department of Dermatology, Mackay Memorial Hospital, Taipei, Taiwan.
Hsiao
Cheng-Hsiang
CH
Tsai
Tsen-Fang
TF
Jee
Shiou-Hwa
SH
D000293:Adolescent; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009182:Mycosis Fungoides / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D018365:Neoplasm, Residual / Q000209:etiology* / Q000378:metabolism / Q000473:pathology*; D010859:Pigmentation Disorders / Q000150:complications / Q000473:pathology*; D016133:Polymerase Chain Reaction; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000378:metabolism; D012074:Remission Induction; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D012880:Skin Pigmentation
D018906:Antineoplastic Agents, Alkylating; D016692:Receptors, Antigen, T-Cell, gamma-delta; D002330:Carmustine